Endosialin/CD248 may be a potential therapeutic target to prevent the invasion and metastasis in osteosarcoma.
endosialin
invasion
metastasis
osteosarcoma
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
17
04
2021
accepted:
24
09
2021
entrez:
3
1
2022
pubmed:
4
1
2022
medline:
4
1
2022
Statut:
ppublish
Résumé
Endosialin/CD248/tumor endothelial marker 1 is classified as a C-type lectin-like transmembrane receptor, found on the plasma membrane of activated mesenchymal cells, which binds to fibronectin. Although endosialin is expressed at high levels in stem-like cells of sarcomas, its role has not been fully uncovered. The present study aimed to determine whether endosialin expression is associated with tumor progression and metastasis, and whether endosialin has the potential to act as a novel therapeutic target in osteosarcoma (OS) using MORAb-004/ontuxizumab, a humanized monoclonal antibody, which targets the type C lectin domain of endosialin. The results demonstrated that endosialin was highly expressed in OSs with metastatic disease. Furthermore, MORAb-004 had no cytostatic effect on OS cells
Identifiants
pubmed: 34976154
doi: 10.3892/ol.2021.13160
pii: OL-23-02-13160
pmc: PMC8674875
doi:
Types de publication
Journal Article
Langues
eng
Pagination
42Informations de copyright
Copyright: © Kondo et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):17965-70
pubmed: 17986615
Oncotarget. 2016 Mar 15;7(11):13082-92
pubmed: 26909615
PLoS One. 2020 Jul 28;15(7):e0232565
pubmed: 32722676
Am J Pathol. 2000 Nov;157(5):1523-35
pubmed: 11073812
Cancer. 2019 Jul 15;125(14):2445-2454
pubmed: 31034598
Mol Med Rep. 2015 Oct;12(4):5665-70
pubmed: 26300407
Pathobiology. 2009;76(5):267-73
pubmed: 19816087
Oncol Lett. 2017 Jul;14(1):681-686
pubmed: 28693221
Oncotarget. 2015 Sep 22;6(28):25429-40
pubmed: 26327620
Cancer Res. 2016 Sep 15;76(18):5313-25
pubmed: 27635044
Oncotarget. 2019 Jan 29;10(9):993-1009
pubmed: 30847027
J Biol Chem. 2001 Mar 9;276(10):7408-14
pubmed: 11084048
Mol Cancer Ther. 2008 Aug;7(8):2536-46
pubmed: 18723498
Rheumatol Ther. 2017 Jun;4(1):25-43
pubmed: 27933467
Clin Cancer Res. 2015 Mar 15;21(6):1281-8
pubmed: 25398449
Cancer Biol Ther. 2010 Jun 1;9(11):908-15
pubmed: 20484976
Oncol Lett. 2018 Jun;15(6):9845-9851
pubmed: 29928358
Sarcoma. 2011;2011:959248
pubmed: 21559216
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3351-6
pubmed: 16492758
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Oncol Lett. 2018 Apr;15(4):4423-4426
pubmed: 29556289
Am J Physiol Heart Circ Physiol. 2010 Feb;298(2):H719-25
pubmed: 19933413